Recent Advances in the Application of Cucurbitacin B as an Anticancer Agent
International Journal of Molecular Sciences · 19.08.2025 · 26 (16) · 8003
DOI: 10.3390/ijms26168003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.08.2025. Verfasst von Dongge Yin und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China. Hauptthemen laut MEDLINE: Triterpenes, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Young Elite Scientists Sponsorship Program by the Beijing Natural Science Foundation, the National Natural Science Foundation of China, Beijing Natural Science Foundation.
Abstract (Originalsprache)
Cucurbitacin B (CuB), a tetracyclic triterpenoid compound isolated from Cucurbitaceae plants, exhibits inhibitory effects on various tumor cells (e.g., liver, gastric, and colorectal cancer cells). Since the 1970s–1980s, cucurbitacin tablets containing CuB have been used as an adjuvant therapy for chronic hepatitis and primary liver cancer. CuB exerts anticancer effects through multiple mechanisms: inducing apoptosis, cell cycle arrest (G2/M or S phase), autophagy, and cytoskeleton disruption; inhibiting migration, invasion, and angiogenesis (via VEGF/FAK/MMP-9 and Wnt/β-catenin pathways); regulating metabolic reprogramming and immune responses; inducing pyroptosis, ferroptosis, and epigenetic changes; and reversing tumor drug resistance. These effects are associated with signaling pathways like JAK/STAT, PI3K/Akt/mTOR, and FOXM1-KIF20A. To improve its application potential, strategies such as structural modification (e.g., NO donor conjugation), combination therapy (with gemcitabine or cisplatin), and nanomaterial-based delivery (e.g., liposomes and exosome-mimicking nanoparticles) have been developed to enhance efficacy, reduce toxicity, and improve bioavailability. CuB shows broad-spectrum anticancer activity, but further research is needed to clarify the mechanisms underlying its cell-specific sensitivity and interactions with the immune system. This review systematically summarizes the physicochemical properties, anticancer mechanisms, and strategies for applying CuB and suggests future research directions, providing references for scientific research and clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China.
ORCID-Profile: Xiaoxv Dong, Xingbin Yin
Förderung
- the Young Elite Scientists Sponsorship Program by the Beijing Natural Science Foundation
- the National Natural Science Foundation of China
- Beijing Natural Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Yin, D., Chen, H., Lin, S., Sun, Y., Jing, X., Chang, R., Feng, Y., Dong, X., Qu, C., Ni, J., & Yin, X. (2025). Recent Advances in the Application of Cucurbitacin B as an Anticancer Agent. International Journal of Molecular Sciences, 26(16), 8003. https://doi.org/10.3390/ijms26168003
Vancouver
Yin D, Chen H, Lin S, Sun Y, Jing X, Chang R, et al. Recent Advances in the Application of Cucurbitacin B as an Anticancer Agent. International Journal of Molecular Sciences. 2025;26(16):8003. doi:10.3390/ijms26168003
BibTeX
@article{Yin2025,
author = {Yin, Dongge and Chen, Hongyue and Lin, Shuting and Sun, Yufei and Jing, Xiaohong and Chang, Rongrong and Feng, Yang and Dong, Xiaoxv and Qu, Changhai and Ni, Jian and Yin, Xingbin},
title = {Recent Advances in the Application of Cucurbitacin B as an Anticancer Agent},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {16},
pages = {8003},
doi = {10.3390/ijms26168003}
}
EUVIMED